 | Up a level |
Ferreri, A J M; Illerhaus, G; Doorduijn, J K; Auer, D P; Bromberg, J E C; Calimeri, T; Cwynarski, K; Fox, C P; Hoang-Xuan, K; Malaise, D; Ponzoni, M; Schorb, E; Soussain, C; Specht, L; Zucca, E; Buske, C; Jerkeman, M; Dreyling, M (2024). Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. (In Press). Annals of oncology Elsevier 10.1016/j.annonc.2023.11.010
Moccia, A A; Aeppli, S; Güsewell, S; Bargetzi, M; Caspar, C; Brülisauer, D; Ebnöther, M; Fehr, M; Fischer, N; Ghilardi, G; Krasniqi, F; Lang, N; Mey, U; Mingrone, W; Novak, U; Pfleger, C; Richter, P; Rütti, M; Schmidt, A; Stenner, F; ... (2021). Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematological oncology, 39(2), pp. 196-204. Wiley 10.1002/hon.2830
Hitz, F; Fischer, N; Pabst, Th; Caspar, C; Berthod, G; Eckhardt, K; Berardi Vilei, S; Zucca, E; Mey, U; On behalf of Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (2013). Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Annals of hematology, 92(8), pp. 1033-1040. Berlin: Springer 10.1007/s00277-013-1751-z
